Elevance CEO Bought the Stock Dip

President and CEO Gail K. Boudreaux bought shares of the health insurer after Elevance slashed guidance. (Consumer Technology Association)

Elevance Health stock has tumbled this year, and President and CEO Gail K. Boudreaux just bought a large block of shares of the health insurer.

Elevance shares have lost about a fifth of their value in 2025. Shares had been slipping since mid-April—but they took a nosedive after Elevance slashed earnings guidance while reporting second-quarter numbers after the market close on July 17. The stock plunged 8.4% on the next trading day, July 18.

The day of the drop, Boudreaux paid $2.4 million for 8,500 shares, an average price of $286.94 each. She now owns 151,020 Elevance shares in a personal account, according to a form that Boudreaux filed with the Securities and Exchange Commission.

Elevance declined to comment and didn’t make Boudreaux available for comment. It’s her first purchase of Elevance stock on the open market in years. Boudreaux last bought stock on the open market in January 2020, when she paid $2 million for 7,600 shares, an average price of $263.70. At the time, the company was known as Anthem; it changed its name in May 2022.

A year ago, when Elevance’s stock price was materially higher than now, Boudreaux was selling stock. On July 22, she sold 34,000 shares for $17 million, an average price of $500.98 each. The SEC form detailing the transactions noted that the sales were made through a so-called Rule 10b5-1 trading plan, a device meant to remove the appearance of bias from an insider’s knowledge of nonpublic information. The plans execute trades automatically when preset conditions such as price, volume, and timing are met.

Inside Scoop is a regular Barron’s feature covering stock transactions by corporate executives and board members—so-called insiders—as well as large shareholders, politicians, and other prominent figures. Due to their insider status, these investors are required to disclose stock trades with the Securities and Exchange Commission or other regulatory groups.

Write to Ed Lin at edward.lin@barrons.com